Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志
中国生物工程杂志  2023, Vol. 43 Issue (9): 55-61    DOI: 10.13523/j.cb.2303033
综述     
突变MARCH作用靶点在假病毒产率提升中的应用*
井汇源1,**(),段二珍2,赵攀登1
1 河南牧业经济学院 郑州 450046
2 河南工业大学生物工程学院 郑州 450001
Improvement of the Yield of Pseudoviruses via Mutation of Lysine Residues Targeted by MARCH
JING Hui-yuan1,**(),DUAN Er-zhen2,ZHAO Pan-deng1
1 Henan University of Animal Husbandry and Economy, Zhengzhou 450046, China
2 College of Biological Engineering, Henan University of Technology, Zhengzhou 450001, China
 全文: PDF(842 KB)   HTML
摘要：

抗病毒药物、中和抗体和预防性疫苗是应对新发、再发高致病性和高感染性病毒(如新冠病毒)最有效的策略。然而,涉及上述活病毒的实验操作必须在包含生物安全3级和4级设施的实验室中开展。为了便于评估上述抗病毒制品,研究者开发了基于人类免疫缺陷病毒(human immunodeficiency virus,HIV)和水疱性口炎病毒(vesicular stomatitis virus,VSV)骨架的假病毒包装系统。该系统同时包含靶标病毒的囊膜蛋白表达质粒,使包装好的假病毒具备与野生型病毒相似的受体吸附和膜融合功能。鉴于此,在特定的包装系统中,囊膜蛋白的包装过程对假病毒产率和感染性影响巨大。研究发现膜相关泛素连接酶家族蛋白(membrane-associated RING-CH,MARCH)能够降解病毒囊膜蛋白,下调假病毒产率和感染性。讨论了囊膜蛋白胞内域赖氨酸修饰对假病毒产率影响的研究进展,以期提高囊膜蛋白表达量和加工成熟效率,促进抗病毒药物研发、抗体筛选、疫苗创制和病毒受体鉴定。
关键词： 假病毒;  包装系统;  囊膜蛋白;  赖氨酸修饰    
Abstract:

Therapeutic antiviral drugs, neutralizing antibody and preventive vaccines have been proven to be the most effective control measures towards emerging and reemerging viruses with high pathogenicity and infectivity like SARS-CoV-2. However, the experiments involving live viruses must be carried out in biosafety level 3 (BSL-3) or BSL-4 facilities. To facilitate the evaluation of these antiviral products, the pseudovirus system has been developed based on the human immunodeficiency virus (HIV)/vesicular stomatitis virus (VSV) packaging system, as well as expression plasmids carrying envelope proteins to perform the function of attachment and fusion similar to the wild-type virus. Membrane-associated RING-CH (MARCH) E3 ubiquitin ligase proteins have been reported to downregulate the envelope proteins and significantly affect the yield and infection efficiency of pseudoviruses. This review summarizes the current progress in the effect of engineering MARCH-resistant envelop proteins by lysine modification on the production of pseudoviruses. Apparently, increased expression level from the surfaces of packaging cells and improved processing of the envelope protein in the packaging cells will greatly promote the development of antiviral drugs, antibody screening, vaccine research, and receptor recognition.
Key words: Pseudoviruses    Packaging system    Envelope protein    Lysine residue modification
收稿日期: 2023-03-13 出版日期: 2023-10-08
ZTFLH:  R373.2  
基金资助: * 国家自然科学基金(32002265);河南省科技攻关(202102110095)
通讯作者: ** 电子信箱:lhsjhy@126.com   
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
井汇源
段二珍
赵攀登

引用本文:

井汇源, 段二珍, 赵攀登. 突变MARCH作用靶点在假病毒产率提升中的应用*[J]. 中国生物工程杂志, 2023, 43(9): 55-61.

JING Hui-yuan, DUAN Er-zhen, ZHAO Pan-deng. Improvement of the Yield of Pseudoviruses via Mutation of Lysine Residues Targeted by MARCH. China Biotechnology, 2023, 43(9): 55-61.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2303033    或    https://manu60.magtech.com.cn/biotech/CN/Y2023/V43/I9/55

图1  假病毒的构建策略
图2  病毒膜融合蛋白结构和功能域示意图
图3  MARCH家族蛋白结构示意图
[1] Wen X J, Zhang L, Liu Q, et al. Screening and identification of HTNVpv entry inhibitors with high-throughput pseudovirus-based chemiluminescence. Virologica Sinica, 2022, 37(4): 531-537.
doi: 10.1016/j.virs.2022.04.015
[2] Zhang Y, Wei Y Q, Li Y L, et al. IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability. PLoS Neglected Tropical Diseases, 2021, 15(3): e0008403.
doi: 10.1371/journal.pntd.0008403
[3] Ma J, Chen R F, Huang W J, et al. In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus. Human Vaccines & Immunotherapeutics, 2019, 15(10): 2286-2294.
[4] Cheng M L, Yang Y X, Liu Z Y, et al. Pathogenicity and structural basis of zika variants with glycan loop deletions in the envelope protein. Journal of Virology, 2022, 96(23): e0087922.
doi: 10.1128/jvi.00879-22
[5] Xiong Q, Cao L, Ma C B, et al. Close relatives of MERS-CoV in bats use ACE 2 as their functional receptors. Nature, 2022, 612(7941): 748-757.
doi: 10.1038/s41586-022-05513-3
[6] Leach A, Ilca F T, Akbar Z, et al. A tetrameric ACE 2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. Antiviral Research, 2021, 194(105147):1-7.
[7] Arimori T, Ikemura N, Okamoto T, et al. Engineering ACE2 decoy receptors to combat viral escapability. Trends in Pharmacological Sciences, 2022, 43(10): 838-851.
doi: 10.1016/j.tips.2022.06.011
[8] Cooper L, Galvan Achi J, Rong L J. Comparative analyses of small molecule and antibody inhibition on glycoprotein-mediated entry of Měnglà virus with other filoviruses. Journal of Medical Virology, 2022, 94(7): 3263-3269.
doi: 10.1002/jmv.27739 pmid: 35332563
[9] Jeong K, Chang J, Park S M, et al. Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay. Antiviral Research, 2023, 209: 105473.
doi: 10.1016/j.antiviral.2022.105473
[10] Tada T, Zhang Y Z, Fujita H, et al. MARCH8: the tie that binds to viruses. The FEBS Journal, 2022, 289(13): 3642-3654.
doi: 10.1111/febs.v289.13
[11] Villalón-Letelier F, Farrukee R, Londrigan S L, et al. Isoforms of human MARCH 1 differ in ability to restrict influenza A viruses due to differences in their N terminal cytoplasmic domain. Viruses, 2022, 14(11): 2549.
doi: 10.3390/v14112549
[12] Perry C, Rayat A C M E. Lentiviral vector bioprocessing. Viruses, 2021, 13(2): 268.
doi: 10.3390/v13020268
[13] Cao Y L, Jian F C, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature, 2023, 614(7948): 521-529.
[14] Fujioka Y, Kashiwagi S, Yoshida A, et al. A method for the generation of pseudovirus particles bearing SARS coronavirus spike protein in high yields. Cell Structure and Function, 2022, 47(1): 43-53.
doi: 10.1247/csf.21047 pmid: 35491102
[15] Lee S Y, Kim D W, Jung Y T. Construction of SARS-CoV-2 spike-pseudotyped retroviral vector inducing syncytia formation. Virus Genes, 2022, 58(3): 172-179.
doi: 10.1007/s11262-022-01890-z pmid: 35322356
[16] Wang Z, Zhong K H, Wang G Q, et al. Loss of furin site enhances SARS-CoV-2 spike protein pseudovirus infection. Gene, 2023, 856: 147144.
doi: 10.1016/j.gene.2022.147144
[17] Kalkeri R, Cai Z H, Lin S L, et al. SARS-CoV-2 spike pseudoviruses: a useful tool to study virus entry and address emerging neutralization escape phenotypes. Microorganisms, 2021, 9(8): 1744.
doi: 10.3390/microorganisms9081744
[18] Tien C F, Tsai W T, Chen C H, et al. Glycosylation and S-palmitoylation regulate SARS-CoV-2 spike protein intracellular trafficking. iScience, 2022, 25(8): 104709.
doi: 10.1016/j.isci.2022.104709
[19] Ai J W, Wang X, He X Y, et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host & Microbe, 2022, 30(8): 1077-1083.e4.
[20] Wang X, Zhao X Y, Song J Y, et al. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerging Microbes & Infections, 2022, 11(1): 477-481.
[21] Markosyan R M, Marin M, Zhang Y, et al. The late endosome-resident lipid bis(monoacylglycero)phosphate is a cofactor for Lassa virus fusion. PLoS Pathogens, 2021, 17(9): e1009488.
doi: 10.1371/journal.ppat.1009488
[22] Pennington H N, Lee J. Lassa virus glycoprotein complex review: insights into its unique fusion machinery. Bioscience Reports, 2022, 42(2): 1-21.
[23] Chen Y L, Wang F, Yin L W, et al. Structural basis for a human broadly neutralizing influenza A hemagglutinin stem-specific antibody including H17/18 subtypes. Nature Communications, 2022, 13(1): 1-13.
doi: 10.1038/s41467-021-27699-2
[24] Luo M X, Zhou B, Reddem E R, et al. Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. Emerging Microbes & Infections, 2023, 12(1): 2146538.
[25] Alfadhli A, Romanaggi C, Barklis R L, et al. Analysis of HIV-1 envelope cytoplasmic tail effects on viral replication. Virology, 2023, 579: 54-66.
doi: 10.1016/j.virol.2022.12.017 pmid: 36603533
[26] Zhang X J, Wang C, Chen B H, et al. Crystal structure of refolding fusion core of lassa virus GP2 and design of lassa virus fusion inhibitors. Frontiers in Microbiology, 2019, 10: 1829.
doi: 10.3389/fmicb.2019.01829 pmid: 31456769
[27] Wang L L, Estrada L, Wiggins J, et al. Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses. Antiviral Research, 2022, 206: 105399.
doi: 10.1016/j.antiviral.2022.105399
[28] Luo J, Qin H, Lei L, et al. Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice. Frontiers in Immunology, 2022, 13: 1054005.
doi: 10.3389/fimmu.2022.1054005
[29] Wang M, Sun Z Z, Cui C X, et al. Structural insights into alphavirus assembly revealed by the cryo-EM structure of getah virus. Viruses, 2022, 14(2): 327.
doi: 10.3390/v14020327
[30] Zhou K, Si Z, Ge P, et al. Atomic model of vesicular stomatitis virus and mechanism of assembly. Nature Communications, 2022, 13(1): 1-13.
doi: 10.1038/s41467-021-27699-2
[31] Zhang X, Hong J P, Zhong L, et al. Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119(32): e2202371119.
[32] Johnson M C, Lyddon T D, Suarez R, et al. Optimized pseudotyping conditions for the SARS-CoV-2 spike glycoprotein. Journal of Virology, 2020, 94(21): e01062-e01020.
[33] Zhang Y Z, Ozono S, Tada T, et al. MARCH8 targets cytoplasmic lysine residues of various viral envelope glycoproteins. Microbiology Spectrum, 2022, 10(1): e0061821.
doi: 10.1128/spectrum.00618-21
[34] Chen H Y, Huang C, Tian L, et al. Cytoplasmic tail truncation of SARS-CoV-2 spike protein enhances titer of pseudotyped vectors but masks the effect of the D614G mutation. Journal of Virology, 2021, 95(22): e0096621.
doi: 10.1128/JVI.00966-21
[35] Mekkaoui L, Bentley E, Ferrari M, et al. Optimised method for the production and titration of lentiviral vectors pseudotyped with the SARS-CoV-2 spike. Bio-Protocol, 2021, 11(16): e4194.
doi: 10.21769/BioProtoc.4194 pmid: 34541054
[36] Havranek K, Jimenez A, Acciani M, et al. SARS-CoV-2 spike alterations enhance pseudoparticle titers and replication-competent VSV-SARS-CoV-2 virus. Viruses, 2020, 12(12): 1465.
doi: 10.3390/v12121465
[37] Villalón-Letelier F, Brooks A G, Londrigan S L, et al. MARCH8 restricts influenza A virus infectivity but does not downregulate viral glycoprotein expression at the surface of infected cells. mBio, 2021, 12(5): e0148421.
doi: 10.1128/mBio.01484-21
[38] Zhang Y Z, Tada T, Ozono S, et al. MARCH8 inhibits viral infection by two different mechanisms. eLife, 2020, 9: 57763.
[39] Li C, Shi L, Gao Y, et al. HSC70 inhibits spring viremia of carp virus replication by inducing MARCH8-mediated lysosomal degradation of G protein. Frontiers in Immunology, 2021, 12: 724403.
doi: 10.3389/fimmu.2021.724403
[40] Xu F W, Liu X M, Zhang D, et al. The engineered MARCH8-resistant vesicular stomatitis virus glycoprotein enhances lentiviral vector transduction. Human Gene Therapy, 2021, 32(17-18): 936-948.
doi: 10.1089/hum.2020.292
[41] Umthong S, Lynch B, Timilsina U, et al. Elucidating the antiviral mechanism of different MARCH factors. mBio, 2021, 12(2): e03264-e03220.
[42] Yu C Q, Li S N, Zhang X F, et al. MARCH8 inhibits Ebola virus glycoprotein, human immunodeficiency virus type 1 envelope glycoprotein, and avian influenza virus H5N1 hemagglutinin maturation. mBio, 2020, 11(5): 1-15.
[43] Lun cheng man, Waheed A A, Majadly A, et al. Mechanism of viral glycoprotein targeting by membrane-associated RING-CH proteins. mBio, 2021, 12(2): 1-26.
[44] Liu X M, Xu F W, Ren L L, et al. MARCH8 inhibits influenza A virus infection by targeting viral M2 protein for ubiquitination-dependent degradation in lysosomes. Nature Communications, 2021, 12(1): 1-13.
doi: 10.1038/s41467-020-20314-w
[45] Zhang Y Z, Tada T, Ozono S, et al. Membrane-associated RING-CH (MARCH) 1 and 2 are MARCH family members that inhibit HIV-1 infection. The Journal of Biological Chemistry, 2019, 294(10): 3397-3405.
doi: 10.1074/jbc.AC118.005907
[46] Tsai T I, Khalili J S, Gilchrist M, et al. ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern. Antiviral Research, 2022, 199: 105271.
doi: 10.1016/j.antiviral.2022.105271
[1] 冯书营, 景爱华, 杨建英. 白斑综合征病毒囊膜蛋白在对虾免疫保护应用中的研究进展[J]. 中国生物工程杂志, 2011, 31(8): 133-138.
[2] 赵赫龙 赵鹏翔 李政 马雪梅 钟儒刚 曾毅. HIV假病毒用于p24抗原检测试剂研制的研究[J]. 中国生物工程杂志, 2010, 30(08): 13-16.
[3] 谢桂煌 赵声兰 陈朝银. 假病毒技术用于抗HIV-1药物筛选及抗药性分析[J]. 中国生物工程杂志, 2010, 30(03): 95-99.
[4] 郑小惠. 胶囊包装系统[J]. 中国生物工程杂志, 1987, 7(2): 64-65.
主管：中国科学院 　主办：中国科学院文献情报中心 　中国生物技术发展中心 　中国生物工程学会